96 related articles for article (PubMed ID: 3967262)
1. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma.
Houghton JA; Cook RL; Lutz PJ; Houghton PJ
Cancer Treat Rep; 1985 Jan; 69(1):91-6. PubMed ID: 3967262
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice.
Houghton JA; Houghton PJ; Green AA
Cancer Res; 1982 Feb; 42(2):535-9. PubMed ID: 7034923
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard.
Horton JK; Houghton PJ; Houghton JA
Cancer Res; 1987 Dec; 47(23):6288-93. PubMed ID: 2890432
[TBL] [Abstract][Full Text] [Related]
5. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
6. Childhood rhabdomyosarcoma xenografts: responses to DNA-interacting agents and agents used in current clinical therapy.
Houghton JA; Cook RL; Lutz PJ; Houghton PJ
Eur J Cancer Clin Oncol; 1984 Jul; 20(7):955-60. PubMed ID: 6430707
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
[TBL] [Abstract][Full Text] [Related]
8. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
Houghton JA; Williams LG; Torrance PM; Houghton PJ
Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.
Lilley ER; Rosenberg MC; Elion GB; Colvin OM; Bigner DD; Friedman HS
Cancer Res; 1990 Jan; 50(2):284-7. PubMed ID: 2295068
[TBL] [Abstract][Full Text] [Related]
10. Growth and characterization of childhood rhabdomyosarcomas as xenografts.
Houghton JA; Houghton PJ; Webber BL
J Natl Cancer Inst; 1982 Mar; 68(3):437-43. PubMed ID: 6950170
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
[TBL] [Abstract][Full Text] [Related]
12. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.
Laskowitz DT; Elion GB; Dewhirst MW; Griffith OW; Savina PM; Blum MR; Prescott DM; Bigner DD; Friedman HS
Radiat Res; 1992 Feb; 129(2):218-23. PubMed ID: 1734453
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(1):45-52. PubMed ID: 7720175
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma.
Hazelton BJ; Houghton JA; Parham DM; Douglass EC; Torrance PM; Holt H; Houghton PJ
Cancer Res; 1987 Aug; 47(16):4501-7. PubMed ID: 3607778
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
18. Correlation between experimentally and clinically demonstrated activity of two new cytotoxic agents in breast cancer.
Bailey MJ; Smith IE
Anticancer Res; 1985; 5(4):419-22. PubMed ID: 3839994
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.
Houghton PJ; Houghton JA; Myers L; Cheshire P; Howbert JJ; Grindey GB
Cancer Chemother Pharmacol; 1989; 25(2):84-8. PubMed ID: 2598403
[TBL] [Abstract][Full Text] [Related]
20. The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft models.
Gidding CE; Germain GS; Dilling MB; Meeuwsen-de Boer TG; Ashmun RA; de Graaf SS; Veverka KA; Kamps WA; Houghton PJ
Cancer Chemother Pharmacol; 2000; 45(1):21-30. PubMed ID: 10647497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]